Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2022-01-14 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物股票交易严重异常波动公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the serious abnormal fluctuation in the stock price of Hangzhou Anxu Biotechnology Co., Ltd. It details the stock price movement over a specific period, the company's investigation into the causes, confirmation of no undisclosed material information, risk warnings to investors, and related regulatory compliance statements. There are no financial statements, earnings data, or detailed financial analysis present. The document serves as a regulatory disclosure about stock price volatility and related risks rather than a financial report or management discussion. It fits the category of a Regulatory Filing (RNS) as it is a compliance announcement about stock trading abnormalities and risk disclosures required by the stock exchange rules.
2022-01-14 Chinese
安旭生物控股股东及实际控制人关于杭州安旭生物科技股份有限公司股票交易异常波动的问询函的回函
Regulatory Filings
2022-01-14 Chinese
安旭生物关于召开2022年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2022 first extraordinary general meeting of shareholders for Hangzhou Anxu Biotechnology Co., Ltd. It details the meeting date, voting methods, agenda items, registration procedures, and includes a proxy authorization form. There is no financial data, earnings, or report content. It is an announcement related to a shareholder meeting, specifically a notice to shareholders about the meeting and voting procedures. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and voting procedures rather than solicitation materials or voting results, it aligns best with Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters and it is not a report publication announcement. Therefore, the classification is PSI with high confidence.
2022-01-12 Chinese
民生证券股份有限公司关于杭州安旭生物科技股份有限公司使用部分超募资金投资建设新项目的核查意见
Regulatory Filings
2022-01-12 Chinese
安旭生物独立董事关于第一届董事会第二十次会议相关事项的独立意见
Board/Management Information Classification · 90% confidence The document is an independent opinion from the independent directors regarding the use of part of the over-raised funds for a new project investment. It references compliance with company law, listing rules, and internal governance documents. The document is short (682 characters) and does not contain financial statements or detailed financial data. It is an opinion related to board meeting matters and the use of funds, not a full report or announcement of voting results. It is not a certification or a regulatory filing in the strict sense but rather a formal independent director opinion on a board matter. This fits best under Board/Management Information (MANG) as it relates to board-level decisions and opinions on company matters.
2022-01-12 Chinese
安旭生物第一届监事会第八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Hangzhou Anxu Biotech Co., Ltd. regarding the approval of using part of the raised funds for new project investment. It includes details about the meeting, voting results, and compliance with relevant laws and regulations. It is not a full financial report, audit report, or earnings release. It is also not a notice of dividend, capital change, or management change. The document is a formal announcement of a board meeting decision, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories and is a regulatory announcement of a corporate decision.
2022-01-12 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.